Fabry Disease Presenting as End-Stage Kidney Disease

Area of Science:

• Genetics and rare diseases
• Lysosomal storage disorders
• Nephrology

Background:

• Fabry disease (FD) is an X-linked genetic disorder caused by pathogenic variants in the GLA gene, leading to alpha-galactosidase enzyme deficiency.
• This deficiency results in the accumulation of globotriosylceramide and related substances in cells, causing multi-systemic complications, particularly affecting the heart, kidneys, and brain.
• Early diagnosis of FD is crucial for timely therapeutic intervention and improved patient outcomes.

Observation:

• A 40-year-old male presented with advanced kidney disease, characterized by elevated creatinine, nephrotic proteinuria, and new-onset hypertension.
• Renal biopsy showed characteristic cytoplasmic inclusions in podocytes and vascular cells, with ultrastructural analysis revealing "zebra" bodies within lysosomes.
• Enzyme assays confirmed near-absent alpha-galactosidase A activity, leading to a diagnosis of advanced FD.

Findings:

• The patient's presentation with end-stage kidney disease at age 40 underscores the potential for late and atypical manifestations of Fabry disease.
• Diagnostic challenges arise from the nonspecific and varied clinical presentations of FD, ranging from early classical symptoms to late-onset non-classical patterns.
• The presence of "zebra" bodies on ultrastructural examination is a key indicator for lysosomal storage disorders like FD.

Implications:

• This case emphasizes the importance of considering Fabry disease in patients presenting with unexplained kidney disease, even in the absence of typical early symptoms.
• Implementing systematic screening strategies for FD in patients with renal impairment could facilitate earlier diagnosis and treatment initiation.
• Understanding both classical and non-classical presentations is vital for improving diagnostic yield and managing FD effectively.